Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18-47.

Article  PubMed  PubMed Central  Google Scholar 

Strongman H, Kausar I, Maher TM. Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv Ther. 2018;35(5):724–36.

Article  PubMed  PubMed Central  Google Scholar 

Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):197.

Article  PubMed  PubMed Central  Google Scholar 

Natsuizaka M, Chiba H, Kuronuma K, Otsuka M, Kudo K, Mori M, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014;190(7):773–9.

Article  PubMed  Google Scholar 

Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010;35(3):496–504.

Article  PubMed  CAS  Google Scholar 

Tsubouchi K, Hamada N, Tokunaga S, Ichiki K, Takata S, Ishii H, et al. Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry. BMJ Open Respir Res. 2023;10(1):e001864.

Article  PubMed  PubMed Central  Google Scholar 

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.

Article  PubMed  Google Scholar 

King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.

Article  PubMed  Google Scholar 

Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017;196(6):756–61.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Diamantopoulos A, Wright E, Vlahopoulou K, Cornic L, Schoof N, Maher TM. The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review. Pharmacoeconomics. 2018;36(7):779–807.

Article  PubMed  PubMed Central  Google Scholar 

U. S. Bureau of Labor Statistics. CPI inflation calculator. 2025. Available from: https://www.bls.gov/data/inflation_calculator.htm. Accessed 11 Feb 2026.

Diamantopoulos A, Schoof N, Esser D, LeReun C. Resource use in idiopathic pulmonary fibrosis: influence of disease progression and exacerbations. Value Health. 2016;19(7):A561.

Article  Google Scholar 

Diamantopoulos A, Maher TM, Schoof N, Esser D, LeReun C. Influence of idiopathic pulmonary fibrosis progression on healthcare resource use. Pharmacoeconomics. 2019;3(1):81–91.

Article  Google Scholar 

Coteur G, Inoue Y, Cottin V, Small M, Siddall J, Langley J, Bonella J, et al. PRS78 Burden of idiopathic pulmonary fibrosis (IPF) on quality of life (QOL), work productivity and healthcare use. Value Health. 2020;23:S732.

Article  Google Scholar 

Lancaster L, Bonella F, Inoue Y, Cottin V, Siddall J, Small M, et al. Idiopathic pulmonary fibrosis: physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology. 2022;27(1):66–75.

Article  PubMed  Google Scholar 

Ortiz ADR, Rodríguez-Nieto MJ, Villar A, Cano-Jiménez E, Ramón A, Armengol S, et al. Characteristics and clinical management of IPF patients in Spain: prospective, observational, multicentric study (OASIS study). Eur Respir J. 2020;56(Suppl. 64):1839.

Strens D, Bondue B, Dahlqvist C, Slabbynk H, Guiot J, Joos GF, et al. Management-related costs of idiopathic pulmonary fibrosis (IPF) in Belgium. Eur Respir J. 2020;56(Suppl. 64):4810.

Google Scholar 

Wuyts WA, Dahlqvist C, Slabbynck H, Schlesser M, Gusbin N, Compere C, et al. Quality of life and healthcare resource use in a real-world patient population with idiopathic pulmonary fibrosis: the PROOF Registry. Pulm Ther. 2022;8(2):181–94.

Article  PubMed  PubMed Central  Google Scholar 

Feng W, Xuan J, Zhang Y, Lu Y, Ren M, Fan F, et al. Economic burden of idiopathic pulmonary fibrosis (Ipf) in China. Value Health. 2018;21(Suppl. 3):S408.

Article  Google Scholar 

Zheng XF, Xie BB, Liu Y, Zhu M, Zhang S, Ban C, et al. Direct medical costs of hospitalized patients with idiopathic pulmonary fibrosis in a tertiary hospital in China. Chin Med J (Engl). 2020;133(20):2498–500.

Article  PubMed  PubMed Central  Google Scholar 

Kim SW, Myong J, Yoon HK, Koo JW, Kwon SS, Kim YH. Health care burden and medical resource utilisation of idiopathic pulmonary fibrosis in Korea. Int J Tuberc Lung Dis. 2017;21(2):230–5.

Article  PubMed  CAS  Google Scholar 

Soualmi R, Sidi Ali M, Tabbi I, Gharnaout M, Kadi A, Yildiz L, et al. The clinical and economic burden of idiopathic pulmonary fibrosis in Algeria. Value Health. 2018;21(Suppl. 3):S409.

Article  Google Scholar 

The World Bank. World Bank country and lending groups. 2025. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed 11 Feb 2026.

Naoum P, Athanasakis K, Skroumpelos A, Kyriopoulos J. Idiopathic pulmonary fibrosis: utilization of health services and out-of-pocket health expenditures in Greece. Value Health Reg Issues. 2020;22:44–8.

Article  PubMed  Google Scholar 

Naoum P, Skroumpelos A, Athanasakis K, Kyriopoulos J. Idiopathic pulmonary fibrosis: a cost of illness analysis in Greece. Value Health. 2017;20(9):A643.

Article  Google Scholar 

Coteur G, Mumford A, English B, Small M, Siddall J, Khalid J, et al. PRS20 A Multinational asessment of direct and indirect costs from a survey of patients with idiopathic pulmonary fibrosis (IPF). Value Health. 2020;23:S720.

Google Scholar 

Lew D. PRS3 idiopathic pulmonary fibrosis exacerbations: direct costs of medical resources. Value Health Reg Issues. 2019;19:S77.

Article  Google Scholar 

Ho R, Rufino C, Lisondo C, Alves M. Treatment cost comparison of pirfenidone versus nintedanib on the treatment of idiopathic pulmonary fibrosis. Value Health. 2017;20(9):A893.

Google Scholar 

Papageorgiou L, Skroumpelos A,Samara K, Caporis X. Evaluating the annual cost per response rate of pirfenidone and nintedanib for the treatment of patients with idiopathic pulmonary fibrosis. Value Health. 2017;20(9):A642.

Article  Google Scholar 

Morell F, Esser D, Lim J, Stowasser S, Villacampa A, Nieves D, et al. Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain: results of a Delphi Panel. BMC Pulm Med. 2016;16:7.

Article  PubMed  PubMed Central  Google Scholar 

Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ. 2012;15(5):829–35.

Article  PubMed  Google Scholar 

Raimundo K, Chang E, Broder MS, Alexander K, Zazzali J, Swigris JJ. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2016;16:2.

Article  PubMed  PubMed Central  Google Scholar 

Yu YF, Wu N, Chuang CC, Wang R, Pan X, Benjamin N, et al. Patterns and economic burden of hospitalizations and exacerbations among patients diagnosed with idiopathic pulmonary fibrosis. J Manag Care Spec Pharm. 2016;22(4):414–23.

PubMed  PubMed Central  Google Scholar 

Wu N, Yu Y, Chuang CC, Wang R, Benjamin NN, Coultas DB. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States. J Med Econ. 2015;18(4):249–57.

Article  PubMed  Google Scholar 

Collard HR, Chen SY, Yeh WS, Li Q, Lee YC, Wang A, et al. Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc. 2015;12(7):981–7.

Article  PubMed  Google Scholar 

Hagaman JT, Kinder BW, Eckman MH. Thiopurine S-methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung. 2010;188(2):125–32.

OECD. Health at a glance 2023: OECD indicators. Paris: OECD Publishing; 2023.

Corral M, DeYoung K, Kong AM. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study. BMC Pulm Med. 2020;20(1):188.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Qiu Y, Zhu J, Chopra P, Elpers B, Dieyi C, Byrne C, et al. Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United States. Ther Adv Respir Dis. 2024;18:17534666241280704.